The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 20, Issue 8, 2008, Pages 857-868

  Storr, M A ^a   Yuce B ^b   Andrews, C N ^a   Sharkey, K A ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cannabinoids; Endocannabinoid system; Enteric nervous system; Irritable bowel syndrome; Visceral hypersensitivity

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; GPR119 PROTEIN; GPR55 PROTEIN; RIMONABANT; TARANABANT;

ANXIETY DISORDER; CLINICAL TRIAL; DEGRADATION; DEPRESSION; DIGESTIVE SYSTEM INFLAMMATION; GASTROINTESTINAL TRACT; GENETICS; HUMAN; INTESTINE FLORA; INTESTINE MOTILITY; IRRITABLE COLON; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SECRETION; SYMPTOM; SYNTHESIS; VISCERAL PAIN;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; PAIN; RECEPTORS, CANNABINOID;

EID: 47749156067     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01175.x     Document Type: Review

References (112)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006 130 : 1377 90.
3. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002 97 : 1910 5.
4. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
5. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 346 : 561 4.
6. Howlett AC, Barth F, Bonner TI et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002 54 : 161 202.
7. Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot Essent Fatty Acids 1995 53 : 1 11.
8. Shire D, Carillon C, Kaghad M et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995 270 : 3726 31.
9. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007 152 : 567 75.
10. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002 448 : 410 22.
11. Duncan M, Mouihate A, Mackie K et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 2008 (in press).
12. Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD. Influence of cannabinoids on neurotransmission in rat gastric fundus. Can J Physiol Pharmacol 2002 80 : 67 76.
13. Wright K, Rooney N, Feeney M et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005 129 : 437 53.
14. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000 302 : 73 80.
15. Yuce B, Sibaev A, Broedl U et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol Motil 2007 19 : 744 53.
16. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000 483 : 52 6.
17. Mang CF, Erbelding D, Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 2001 134 : 161 7.
18. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001 1 : 597 603.
19. Hanus L, Abu-Lafi S, Fride E et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001 98 : 3662 5.
20. Sharkey KA, Cristino L, Oland LD et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 2007 25 : 2773 82.
21. Ho WS, Hiley CR. Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 2004 56 : 869 75.
22. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 2000 61 : 3 18.
23. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000 21 : 218 24.
24. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008 7 : 438 55.
25. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003 7 : 469 75.
26. Cravatt BF, Lichtman AH. The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 2002 121 : 135 48.
27. Glaser ST, Kaczocha M, Deutsch DG. Anandamide transport: a critical review. Life Sci 2005 77 : 1584 604.
28. Deutsch DG, Glaser ST, Howell JM et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 2001 276 : 6967 73.
29. Capasso R, Matias I, Lutz B et al. Fatty Acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005 129 : 941 51.
30. Duncan M, Thomas AD, Patel KD, Piomelli D, Sharkey KA. The distribution and function of monoacylglycerollipase, an endogenous cannabinoid inactivation enzyme, in the enteric nervous system. Gastroenterology 2008 134 : A686.
31. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006 20 : 568 70.
32. D'Argenio G, Petrosino S, Gianfrani C et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 2007 85 : 523 30.
33. van der Stelt M, Trevisani M, Vellani V et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J 2005 24 : 3026 37.
34. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998 12 : 1035 44.
35. Liu J, Batkai S, Pacher P et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003 278 : 45034 9.
36. Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007 56 : 1770 98.
37. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992 102 : 102 8.
38. Bazzocchi G, Ellis J, Villanueva-Meyer J, Reddy SN, Mena I, Snape WJ, Jr. Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. Gastroenterology 1991 101 : 1298 306.
39. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001 96 : 1499 506.
40. Bassotti G, Chistolini F, Marinozzi G, Morelli A. Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome. Digestion 2003 68 : 178 83.
41. Bazzocchi G, Ellis J, Villanueva-Meyer J et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990 98 : 686 93.
42. Sullivan MA, Cohen S, Snape WJ, Jr. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 1978 298 : 878 83.
43. Drossman DA, Morris CB, Hu Y et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005 128 : 580 9.
44. Debongnie JC, Phillips SF. Capacity of the human colon to absorb fluid. Gastroenterology 1978 74 : 698 703.
45. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001 48 : 859 67.
46. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004 141 : 1335 45.
47. Pinto L, Capasso R, Di Carlo G, Izzo AA. Endocannabinoids and the gut. Prostaglandins Leukot Essent Fatty Acids 2002 66 : 333 41.
48. 1 receptors in guinea-pig small intestine. Br J Pharmacol 1996 118 : 2199 205.
49. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997 121 : 1557 66.
50. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005 83 : 944 54.
51. Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol 2006 148 : 191 9.
52. 1 receptors in human ileum. Br J Pharmacol 1998 125 : 1393 5.
53. Guagnini F, Valenti M, Mukenge S et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 2006 55 : 946 53.
54. Manara L, Croci T, Guagnini F et al. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis 2002 34 : 262 9.
55. Izzo AA, Fezza F, Capasso R et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001 134 : 563 70.
56. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999 384 : 37 42.
57. Pinto L, Izzo AA, Cascio MG et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002 123 : 227 34.
58. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999 384 : 37 42.
59. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007 293 : G137 45.
60. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006 18 : 831 8.
61. Ruilope LM, Despres JP, Scheen A et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008 26 : 357 67.
62. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005 353 : 2121 34.
63. Addy C, Rothenberg P, Li S et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol 2008 48 : 734 44.
64. Dziadulewicz EK, Bevan SJ, Brain CT et al. Naphthalen-1-yl-(4- pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB(1)/CB(2) dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 2007 50 : 3851 6.
65. Anand P, Aziz Q, Willert R, Van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol Motil 2007 19 : 29 46.
66. Azpiroz F, Bouin M, Camilleri M et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007 19 : 62 88.
67. Aziz Q. Visceral hypersensitivity: fact or fiction. Gastroenterology 2006 131 : 661 4.
68. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002 51 (Suppl. 1 i41 4.
69. Holtmann G. IBS: a syndrome or many diseases? Best Pract Res Clin Gastroenterol 2004 18 (Suppl. 91 7.
70. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, Mcquay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001 323 : 13 6.
71. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007 152 : 624 32.
72. Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H. Pharmacological evaluation of a novel cannabinoid 2 (CB(2)) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 2008 106 : 219 24.
73. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006 18 : 949 56.
74. Hillsley K, McCaul C, Aerssens J et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil 2007 19 : 769 77.
75. Miranda A, Nordstrom E, Mannem A, Smith C, Banerjee B, Sengupta JN. The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis. Neuroscience 2007 148 : 1021 32.
76. Ward SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003 465 : 121 35.
77. Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 2008 28 : 1064 75.
78. Chan CL, Facer P, Davis JB et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003 361 : 385 91.
79. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1 expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008 57 : 923 9.
80. Oddsson E, Rask-Madsen J, Krag E. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea. Scand J Gastroenterol 1978 13 : 408 16.
81. Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol 2000 409 : 207 11.
82. MacNaughton WK, Van Sickle MD, Keenan CM, Cushing K, Mackie K, Sharkey KA. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 2004 286 : G863 71.
83. Izzo AA, Capasso F, Costagliola A et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 2003 125 : 765 74.
84. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008 153 : 263 70.
85. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007 26 : 535 44.
86. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006 101 : 1894 9.
87. Ruigomez A, Garcia Rodriguez LA, Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 2007 5 : 465 9.
88. Tornblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol 2007 5 : 461 4.
89. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002 123 : 1972 9.
90. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004 126 : 693 702.
91. Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, Capasso F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000 129 : 1627 32.
92. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006 291 : G364 71.
93. Massa F, Marsicano G, Hermann H et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004 113 : 1202 9.
94. 2 receptors. J Mol Med 2008 (in press).
95. Massa F, Sibaev A, Marsicano G, Blaudzun H, Storr M, Lutz B. Vanilloid receptor (TRPV-1) deficient mice show increased susceptibility to dinitrobenzene sulfonic acid-induced colitis. J Mol Med 2006 84 : 142 6.
96. Martelli L, Ragazzi E, Di Mario F et al. A potential role for the Vanilloid Receptor TRPV1 in the therepeutic effect of curcumin in Dinitrobenzensulfonic acid-induced colitis in mice. Neurogastroenterol Motil 2007 19 : 668 74.
97. Storr M. TRPV1 in colitis: is it a good or a bad receptor? Neurogastroenterol Motil 2007 19 : 625 9.
98. Sibaev A, Massa F, Yuce B et al. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med 2006 84 : 513 20.
99. Kimball ES, Palmer JM, D'Andrea MR, Hornby PJ, Wade PR. Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice. Am J Physiol Gastrointest Liver Physiol 2005 288 : G1266 73.
100. Traub RJ, Wang G. Colonic inflammation decreases thermal sensitivity of the forepaw and hindpaw in the rat. Neurosci Lett 2004 359 : 81 4.
101. Palecek J, Willis WD. The dorsal column pathway facilitates visceromotor responses to colorectal distention after colon inflammation in rats. Pain 2003 104 : 501 7.
102. Massi P, Vaccani A, Parolaro D. Cannabinoids, immune system and cytokine network. Curr Pharm Des 2006 12 : 3135 46.
103. Gkoumassi E, Dekkers BG, Droge MJ et al. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. Br J Pharmacol 2007 151 : 1041 8.
104. Mormina ME, Thakur S, Molleman A, Whelan CJ, Baydoun AR. Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol 2006 540 : 183 90.
105. Kajander K, Myllyluoma E, Rajilic-Stojanovic M et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008 27 : 48 57.
106. Verdu EF, Bercik P, Verma-Gandhu M et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006 55 : 182 90.
107. Ait-Belgnaoui A, Han W, Lamine F et al. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006 55 : 1090 4.
108. Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007 13 : 35 7.
109. Levy RL, Jones KR, Whithehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: hereditary and social learning both contribute to etiology. Gastroenterology 2001 121 : 799 804.
110. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002 99 : 8394 9.
111. Camilleri M, Carlson P, McKinzie S et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 2008 294 : G13 9.
112. Russo EB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 2004 25 : 31 9.